Susceptibility of breast cancer cells to an oncolytic matrix (M) protein mutant of vesicular stomatitis virus.
about
Potential of vesicular stomatitis virus as an oncolytic therapy for recurrent and drug-resistant ovarian cancer.The strength of the T cell response against a surrogate tumor antigen induced by oncolytic VSV therapy does not correlate with tumor controlOncolytic vesicular stomatitis virus induces apoptosis in U87 glioblastoma cells by a type II death receptor mechanism and induces cell death and tumor clearance in vivoChanges in Susceptibility to Oncolytic Vesicular Stomatitis Virus during Progression of Prostate Cancer.VEGF-D-enhanced lymph node metastasis of ovarian cancer is reversed by vesicular stomatitis virus matrix protein.Variation in susceptibility of human malignant melanomas to oncolytic vesicular stomatitis virus.Murine Tumor Models for Oncolytic Rhabdo-Virotherapy.Molecular determinants of susceptibility to oncolytic vesicular stomatitis virus in pancreatic adenocarcinoma.Vesicular stomatitis virus as an oncolytic agent against pancreatic ductal adenocarcinoma.Evaluation of vesicular stomatitis virus mutant as an oncolytic agent against prostate cancer.STAT3 inhibition reduces toxicity of oncolytic VSV and provides a potentially synergistic combination therapy for hepatocellular carcinoma.Virion-associated complement regulator CD55 is more potent than CD46 in mediating resistance of mumps virus and vesicular stomatitis virus to neutralization.Oncotargeting by Vesicular Stomatitis Virus (VSV): Advances in Cancer Therapy.
P2860
Q33579385-185D5394-FF8F-442C-ADF6-E00FE42D0042Q33724224-D193882F-2722-408A-829C-D8EB6A35D3F3Q35077031-1EFDE2C3-4F8D-4EDD-A287-DFEDF360B987Q35641491-091935D0-DC46-4037-97C5-0B3C747BDA33Q36025796-2E7E3421-FABE-48A5-B457-5A29FC13E21DQ36579405-B481972E-6CED-46C9-A4C4-A15E8A4E1CB0Q36751597-CE6D64FD-8A40-4EBC-8AD7-9DA1303ABB02Q37646792-603A5190-BE37-4FE4-9B77-B5E87B0F1ABAQ39413447-92B69BBE-8C73-4DA4-BBEA-99A1EF9E8E1EQ41379521-421577FE-8F12-4657-8440-5956DE0D2B0AQ42144822-D1B68464-BAB7-446E-8B45-9C78FDE8352CQ42326374-D1CF8D8F-80FE-4036-B385-3EC587B7C0B7Q52688581-710AA8B0-8BAA-438A-8F0E-46BEE51D0C9C
P2860
Susceptibility of breast cancer cells to an oncolytic matrix (M) protein mutant of vesicular stomatitis virus.
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
2010年论文
@zh
2010年论文
@zh-cn
name
Susceptibility of breast cance ...... of vesicular stomatitis virus.
@en
type
label
Susceptibility of breast cance ...... of vesicular stomatitis virus.
@en
prefLabel
Susceptibility of breast cance ...... of vesicular stomatitis virus.
@en
P2093
P2860
P356
P1433
P1476
Susceptibility of breast cance ...... of vesicular stomatitis virus.
@en
P2093
P2860
P2888
P304
P356
10.1038/CGT.2010.46
P577
2010-08-20T00:00:00Z